Skip to main content

Table 1 Summary of Kaplan–Meier survival analysis of the E0771 in-vivo study (Fig. 3)

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

  Median survival
  Control (c44) mch1N11 aPD-1 mch1N11 + aPD-1
Days 25 32 55 Undefined
Hazard ratio 0.1915 0.089 0.04557
CI of HR at 95 % 0.003086–0.03911 0.0001420–0.004134 3.222 × 10–5–0.001361
Mice with complete regression 0 0 2 6
  1. Data include median survival (days), hazard ratio (HR) confidence interval (CI) at 95 % of HR, and number of animals with each treatment that experienced complete tumor regression
\